期刊文献+

上海地区氯吡格雷药物代谢基因检测室间质量评价 被引量:3

External quality assessment for clopidogrel therapy-related genotyping in Shanghai
下载PDF
导出
摘要 目的通过开展氯吡格雷药物代谢基因——细胞色素P450 2C19(CYP2C19)*2、*3、*17位点检测室间质量评价(简称室间质评)项目,评估参评临床实验室的检测能力及存在的问题。方法 2015年2次室间质评样本盘均分为2组,每组各包含5支样本。要求参评实验室收到样本后在规定时间内检测样本并网上上报检测结果。依据回报结果计算各实验室成绩,汇总不同位点的总体符合率,并分析检测方法和试剂的符合率。结果 2015年2次室间质评分别收到16份和17份有效回报结果,成绩满分的实验室分别占93.75%和88.24%,CYP2C19*2、*3和*17检测总符合率分别为95.00%、95.00%、100.00%和98.82%、98.82%、95.00%。2次室间质评中,使用自配试剂进行检测的实验室分别占37.5%和35.3%,满分实验室占83.33%和83.33%。使用注册试剂检测实验室成绩为满分的分别占100%和90.91%。结论各实验室在CYP2C19基因各位点检测总体准确率很高,但个别实验室检测能力有待提高。临床实验室的质量控制对于保证检测结果准确性具有十分重要的作用。 Objective Through external quality assessment for clopidogrel therapy-related genotyping for cytochrome P450 2C19(CYP2C19)*2,*3 and *17,to evaluate and discuss the problems in clinical laboratories participated in the programs. Methods The sample panel of external quality assessment 2015 contained 2 different groups,and each group consisted of 5 different samples. Participating laboratories were asked to report the results before deadlines. The scores of these laboratories were calculated based on their results,and the overall coincidence rates of different loci,methods and reagents were calculated. Results External quality assessment 2015 for clopidogrel therapy-related genotyping was set twice a year. A total of 16 and 17 valid laboratory results were received respectively. About 93.75% and 88.24% of the laboratories submitted correct results for all samples. The overall coincidence rates of CYP2C19 *2,*3 and *17 were 95.00%,95.00%,100.00% and 98.82%,98.82%,95.00%,respectively. The laboratories using laboratory-developed tests accounted for 37.5% and 35.3% of all participating laboratories,of which 83.33% and 83.33% of them got full marks in 2 programs of external quality assessment 2015.Meanwhile,100% and 90.91% of laboratories using registered reagents got full marks. Conclusions The overall accuracy rate of participating laboratories is high,while some laboratories' performance still needs to be improved.Quality controls in clinical laboratories are essential to assure the accuracy of results.
作者 鲍芸 肖艳群 蒋玲丽 王雪亮 杨依绡 王华梁 BAO Yun;XIAO Yanqun;JIANG Lingli;WANG Xueliang;YANG Yixiao;WANG Hualiang(Shanghai Center for Clinical Laboratory,Shanghai 200126,China)
出处 《检验医学》 CAS 2017年第3期229-233,共5页 Laboratory Medicine
基金 上海市卫生和计划生育委员会重要疾病联合攻关项目(2013ZYJB0010)
关键词 氯吡格雷 细胞色素P4502C19 基因检测 室间质量评价 Clopidogrel Cytochrome P450 2C19 Genotyping External quality assessment
  • 相关文献

参考文献2

二级参考文献7

  • 1Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active me- tabolite[J]. Drug Metab Dispos,2010,38(1) : 92 - 99. W.
  • 2ilkinson GR. Drug metabolism and variability among patients in drug response[J]. N Engl J Med,2005,352(21) :2211 - 2221.
  • 3Damani SB, Topoi EJ. The case for routine genotyping in dual -an- tiplatelet therapy[J]. J Am Coil Cardiol,2010,56(2):109- 111.
  • 4Xie HG,Kim RB,Wood AJ,et al. Molecular basis of ethnic differ- ences in drug disposition and response[J]. Annu Rev Pharmaeol Toxieol,2001,41:815 - 850.
  • 5Beitelshees AL, Horenstein RB, Vesely MR, et al. Pharmacogenet- ics and clopidogrel response in patients undergoing percutaneous coronary interventions[J]. Clin Pharrnacol Ther, 2011,89 (3) : 455 - 459.
  • 6Snoep JD, Hovens MM, Eikenboom JC, et al. ClopidogreI nonre-sponsiveness in patients undergoing percutaneous coronary inter- vention with stenting: A systematic review and meta- analysis [J]. Am Heart J,2007,154:221 - 231.
  • 7Tazaki J, Jinnai T, Tada T,et al. Prediction of clopidogrel low re- sponders by a rapid CYP2C19 activity test [J]. J Atheroscler Thromb,2012,19(2) : 186 - 193.

共引文献71

同被引文献20

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部